Calliditas Therapeutics AB
DelistedCIK 1795579fmd_1F7C3HMR55HAK7KPTJ6DRFPT31Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2024, 13 periods
Latest annual · FY2023
Millions- Total revenues
- 1,207
- Gross profit
- 1,146
- Operating income
- (373)
- Net income
- (466)
- Free cash flow
- (447)
Latest quarter · Q2 FY2024
Millions- Total revenues
- 560
- Gross profit
- 506
- Operating income
- (32)
- Net income
- (47)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- +1,013.6%
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
Calliditas Therapeutics AB financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | SEK 1.2 billion | SEK 802.9 million | +50.3% | 20-F 2024-04-24 · proof |
| Gross profit | SEK 1.1 billion | SEK 787.7 million | +45.5% | 20-F 2024-04-24 · proof |
| Operating income | -SEK 373.1 million | -SEK 421.9 million | 20-F 2024-04-24 · proof | |
| Net income | -SEK 466.2 million | -SEK 412.3 million | 20-F 2024-04-24 · proof | |
| Cash from operating activities | -SEK 434.7 million | -SEK 311.4 million | 20-F 2024-04-24 · proof | |
| Free cash flow | -SEK 447.4 million | -SEK 313.9 million | 20-F 2024-04-24 · proof | |
| Total assets | SEK 1.9 billion | SEK 2 billion | -4.8% | 20-F 2024-04-24 · proof |
| Total liabilities | SEK 1.5 billion | SEK 1.2 billion | +28.5% | 6-K 2024-08-13 · proof |
| Cash and cash equivalents | SEK 973.7 million | SEK 1.2 billion | -22% | 20-F 2024-04-24 · proof |
- What was Calliditas Therapeutics AB's revenue in fiscal 2023?
- Calliditas Therapeutics AB reported revenue of SEK 1.2 billion for fiscal 2023 (the year ended Dec 31, 2023), against SEK 802.9 million the year before (+50.3%). Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What was Calliditas Therapeutics AB's gross profit in fiscal 2023?
- Calliditas Therapeutics AB reported gross profit of SEK 1.1 billion for fiscal 2023 (the year ended Dec 31, 2023), against SEK 787.7 million the year before (+45.5%). Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What was Calliditas Therapeutics AB's operating income in fiscal 2023?
- Calliditas Therapeutics AB reported operating income of -SEK 373.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -SEK 421.9 million the year before. Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What was Calliditas Therapeutics AB's net income in fiscal 2023?
- Calliditas Therapeutics AB reported net income of -SEK 466.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -SEK 412.3 million the year before. Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What was Calliditas Therapeutics AB's cash from operating activities in fiscal 2023?
- Calliditas Therapeutics AB reported cash from operating activities of -SEK 434.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -SEK 311.4 million the year before. Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What was Calliditas Therapeutics AB's free cash flow in fiscal 2023?
- Calliditas Therapeutics AB reported free cash flow of -SEK 447.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -SEK 313.9 million the year before. Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What are Calliditas Therapeutics AB's total assets?
- As of Dec 31, 2023, Calliditas Therapeutics AB reported total assets of SEK 1.9 billion, against SEK 2 billion a year earlier (-4.8%). Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
- What are Calliditas Therapeutics AB's total liabilities?
- As of Dec 31, 2023, Calliditas Therapeutics AB reported total liabilities of SEK 1.5 billion, against SEK 1.2 billion a year earlier (+28.5%). Source: the 6-K filed with the SEC on Aug 13, 2024. SEC
- What are Calliditas Therapeutics AB's cash and cash equivalents?
- As of Dec 31, 2023, Calliditas Therapeutics AB reported cash and cash equivalents of SEK 973.7 million, against SEK 1.2 billion a year earlier (-22%). Source: the 20-F filed with the SEC on Apr 24, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1795579&period_type=annual&limit=5"Information only, not investment advice.